ClinicalTrials.gov
public full text
Public Domain
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will be conducted over a 3 month period.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder#1137471
- Internet-delivered Cognitive-behaviour Therapy for Child and Adolescent Body Dysmorphic Disorder#835050
- CBT as an Adjunct to SRIs in the Treatment of BDD#830956
- Internet Cognitive Behavior Therapy (CBT) for Body Dysmorphic Disorder (BDD)#910560
- DWP05195 in Healthy Adult Male Volunteers#1031203
Record · ID 891606
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive